920 reports of this reaction
1.4% of all PHENYLEPHRINE HYDROCHLORIDE reports
#3 most reported adverse reaction
JOINT SWELLING is the #3 most commonly reported adverse reaction for PHENYLEPHRINE HYDROCHLORIDE, manufactured by Belmora LLC. There are 920 FDA adverse event reports linking PHENYLEPHRINE HYDROCHLORIDE to JOINT SWELLING. This represents approximately 1.4% of all 65,609 adverse event reports for this drug.
Patients taking PHENYLEPHRINE HYDROCHLORIDE who experience joint swelling should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
JOINT SWELLING is a less commonly reported adverse event for PHENYLEPHRINE HYDROCHLORIDE, but still significant enough to appear in the safety profile.
In addition to joint swelling, the following adverse reactions have been reported for PHENYLEPHRINE HYDROCHLORIDE:
The following drugs have also been linked to joint swelling in FDA adverse event reports:
JOINT SWELLING has been reported as an adverse event in 920 FDA reports for PHENYLEPHRINE HYDROCHLORIDE. This does not prove causation, but indicates an association observed in post-market surveillance data.
JOINT SWELLING accounts for approximately 1.4% of all adverse event reports for PHENYLEPHRINE HYDROCHLORIDE, making it one of the most commonly reported side effect.
If you experience joint swelling while taking PHENYLEPHRINE HYDROCHLORIDE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.